This is a working overview of bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-15 and is reviewed periodically as new material appears.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
=== Greece === Members of the Hellenic Parliament are known as vouleftés (βουλευτής, "councillors") in Greek, which is rendered into English as "members of parliament". The Vouli is a unicameral legislature of 300 constituency members, each elected for a four-year term.
The aorta is the root systemic artery (i.e., main artery). In humans, it receives blood directly from the left ventricle of the heart via the aortic valve. As the aorta branches and these arteries branch, in turn, they become successively smaller in diameter, down to the arterioles. The arterioles supply capillaries, which in turn empty into venules. The first branches off of the aorta are the coronary arteries, which supply blood to the heart muscle itself. These are followed by the branches of the aortic arch, namely the brachiocephalic artery, the left common carotid, and the left subclavian arteries.
=== International travel === Zolpidem is among the agents used in the short-term management of insomnia associated with jet lag, typically at doses of 5–10 mg. Its clinical use, similar to that of other hypnotics, is constrained by the potential for adverse effects and dependence, and guidelines generally recommend limiting treatment duration to short periods, usually under one week.
24 August The first publicized combat refusal of American soldiers in the war took place when "A" Company of the 196th Light Infantry Brigade, 23rd Infantry Division refused to obey the orders of their lieutenant. The battalion commander, Lieutenant Colonel Robert C. Bacon, traveled to the area the next day and reassigned the Lieutenant to another position.
Sources: en.wikipedia.org
This reagent is a good formylating agent and can regenerate the unsubstituted imidazole (with formation of carbon monoxide) upon heating. Yet another reaction involves the acylation of triphenylalkelynephosphoranes.
A 2017 study estimated the top running speed of Tyrannosaurus as 17 mph (27 km/h), speculating that Tyrannosaurus exhausted its energy reserves long before reaching top speed, resulting in a parabola-like relationship between size and speed. Another 2017 study hypothesized that an adult Tyrannosaurus was incapable of running due to high skeletal loads. Using a calculated weight estimate of 7 tons, the model showed that speeds above 11 mph (18 km/h) would have probably shattered the leg bones of Tyrannosaurus. The finding may mean that running was also not possible for other giant theropod dinosaurs like Giganotosaurus, Mapusaurus and Acrocanthosaurus. However, studies by Eric Snively and colleagues, published in 2019 indicate that Tyrannosaurus and other tyrannosaurids were more maneuverable than allosauroids and other theropods of comparable size due to low rotational inertia compared to their body mass combined with large leg muscles. As a result, it is hypothesized that Tyrannosaurus was capable of making relatively quick turns and could likely pivot its body more quickly when close to its prey, or that while turning, the theropod could "pirouette" on a single planted foot while the alternating leg was held out in a suspended swing during a pursuit. The results of this study potentially could shed light on how agility could have contributed to the success of tyrannosaurid evolution. In 2026, Boeye and colleagues analyzed the foot biomechanics of T. rex and determined that its foot likely functioned similarly to modern birds.
== See also == Selenocysteine, another selenium-containing amino acid, but one that is incorporated into specific locations of specific proteins as directed by the genetic code. Selenoprotein Canadian Reference Material of selenomethionine
Sources: en.wikipedia.org
=== Australia and New Zealand === There are 15 recognised specialty medical Colleges in Australia. The majority of these are Australasian Colleges and therefore also oversee New Zealand specialist doctors. These Colleges are:
==== Absorption ==== Tiagabine is nearly completely absorbed (>95%) and has an oral bioavailability of 90%. The time to peak levels is approximately 1 hour, with a range of 0.8 to 1.5 hours. Peak levels occur after 45 minutes in a fasted state and after 2.5 hours when taken with a high-fat meal. A high fat meal decreases peak levels by 40% but does not affect area-under-the-curve levels, indicating that it delays absorption but does not reduce the extent of absorption. Tiagabine was administered with food in clinical trials and it is recommended that it be taken with food. The pharmacokinetics of tiagabine are linear over a dose range of 2 to 24 mg. Steady-state levels are achieved after 2 days of continuous dosing and there is no accumulation with repeated administration. There have been found to be secondary peaks in circulating tiagabine levels which is suggestive of enterohepatic recycling.
== Facilities == Lineage is headquartered in Novi, Michigan, with additional offices around the world. It operates about 223 facilities in North America, including in 37 U.S. states, and warehouses in Australia, Belgium, Canada, China, Denmark, France, Germany, Italy, the Netherlands, New Zealand, Norway, Peru, Poland, Singapore, Spain, Sri Lanka, the United Kingdom, and Vietnam.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.